Low rate of cervical cancer among women with rising incidence of cervical cytological abnormalities. The unlearnt lesson

Objectives: Cervical cancer is preceded by a group of epithelial cell abnormalities. However, there is insufficient data on cervical abnormalities in Jordan and the Middle East at large. The current study aimed at determining the prevalence of different cytological abnormalities in women in Jordan. In addition, it aimed at assessing the age specific cytological abnormalities in these women and analyzing the changing trends of epithelial cell abnormalities in cervical smear over a period of 15 years compared in three periods of five years each. Materials and Methods: 6,455 conventional cervical Papanicolaou (Pap) smear results obtained between January 2000 and December 2014 were retrospectively analyzed. Results: Out of the 6,454 Pap smears analyzed, 5,645 (87.5%) were found adequate for reporting. A total number of 801 (14.2 %) cases had cervical epithelial abnormalities. A significant increase in cytological abnormalities was observed between 2000 and 2014. In addition, a significant increasing trend in cervical cytological abnormalities was noted between 2000 and 2014. The highest percentage of cytological abnormalities (20.1%) was found in women younger than 25 years old. In all of the age groups, the low-grade squamous intraepithelial lesions (LSIL) cytological abnormality was the most prevalent. Conclusions: Invasive cervical cancer is still a killer for young women in the developing countries. The present study may reflect a change in the sociosexual behavior over the last 15 years. The current work highlights the importance of awareness campaigns on the importance of cervical smear and the urgent need for initiating a cervical screening program in Jordan.

Pap smear; Cervical cancer; HPV; Cervical screening program; Jordan.

[1] Hikmat A., Attiga F., Mansour A.: “Cancer care in Jordan”. Hematol. Oncol. Stem Cell Ther., 2015, 8, 64-70.

[2] Ferlay J., Soerjomataram I., Dikshit R., Eser S., Mathers C., Rebelo M., et al.: “Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012”. Int. J. Cancer , 2015, 136, E359.

[3] Stewart S.L., Rim S.H., Gelb C.A.: “Physician knowledge and awareness of CA-125 as a screen for ovarian cancer in the asymptomatic, average-risk population”. Health Educ Behav., 2012, 39, 57.

[4] Ministry of Health Non-Communicable Diseases Directorate Jordan Cancer Registry: “Cancer Incidence in Jordan 2010”. Available at: http://www.moh.gov.jo/Documents/Annual Incidence of

cancer in Jordan 2010.pdf

[5] Guido R.: “Secondary prevention of cervical cancer part 2: initial management of abnormal cervical cancer screening test”. Clin. Obstet. Gynecol., 2014, 57, 292.

[6] Traut H.F., Papanicolaou G.N.: “Cancer of the teurus: the vaginal smear in its diagnosis”. Cal. West. Med., 1943, 59, 121.

[7] Cervical Screening Programme, England: 2000–01: “Statistical Bulletin 2001/22”. London: Government Statistical Service, 2001.

[8] Saslow D., Runowicz C.D., Solomon D., Moscicki A.B., Smith R.A., Eyre H.J., Cohen C.: “American Cancer Society guideline for the early detection of cervical neoplasia and cancer”. CA Cancer J. Clin., 2002, 52, 342.

[9] Weinstock H., Stuart B., Cates W. Jr.: “Sexually transmitted diseases among American youth: incidence and prevalence estimates”. Perspect. Sex. Reprod. Health, 2004, 36, 6.

[10] Trottier H., Franco E.L.: “The epidemiology of genital human papillomavirus infection”. Vaccine, 2006, 24, S1.

[11] Seoud M.: “Extended Middle East and North Africa: cervical cancer and human papillomavirus: can we make the case for prevention in this “relatively” low prevalence region?” Vaccine, 2013, 31 vii.

[12] El-Kak F.: “Sexuality and sexual health: constructs and expressions in the extended Middle East and North Africa”. Vaccine, 2013, 31, G45.

[13] Amarin Z.O., Badria L.F., Obeidat B.R.: “Attitudes and beliefs about cervical smear testing in ever-married Jordanian women”. East Mediterr. Health J., 2008, 14, 389.

[14] Burd E.M.: “Human papillomavirus and cervical cancer”. Clin. Microbiol. Rev., 2003, 16, 1.

[15] Treacy A., Reynolds J., Kay E.W., Leader M., Grace A.: “Has the ThinPrep method of cervical screening maintained its improvement over conventional smears in terms of specimen adequacy?” Diagn. Cytopathol., 2009, 37, 239.

[16] Coskun S., Can H., Turan S.: “Knowledge about cervical cancer risk factors and pap smear testing behavior among female primary health care workers: a study from south Turkey”. Asian Pac. J. Cancer Prev., 2013, 14, 6389.

[17] National Institute for Clinical Excellence (NICE): “NHS Technol-ogy Appraisal Guidance 69. Guidance on the use of liquid-based cytology for cervical screening”. London, 2003. Available at: https://www.nice.org.uk/guidance/ta69/resources/guidance-on-theuse-of-liquidbased-cytology-for-cervical-screening-2294706450373

[18] Sigurdsson K.: “Is a liquid-based cytology more sensitive than a conventional Pap smear?” Cytopathology, 2013, 24, 254.

[19] Al Zaabi M., Al Muqbali S., Al Sayadi T., Al Ameeri S., Coetsee K., Balayah Z., Ortashi O.: “Age specific cytological abnormalities in women screened for cervical cancer in the Emirate of Abu Dhabi”. Asian Pac. J. Cancer Prev., 2015, 16, 6375.

[20] Kapila K., Sharma P.N., George S.S., Al-Shaheen A., Al-Juwaiser A., Al-Awadhi R.: “Trends in epithelial cell abnormalities observed on cervical smears over a 21-year period in a tertiary care hospital in Kuwait”. Sultan Qaboos Univ. Med. J., 2015, 15, e112-5.

[21] Al Nsour M., Brown D.W., Tarawneh M., Haddadin R., Walk H.: “Breast and cervical cancer screening among women in Jordan: findings from the behavioural risk factor surveillance system-2007”. TOPCANJ., 2012, 4, 1.

[22] Maaita M., Barakat M.: “Jordanian women’s attitudes towards cervical screening and cervical cancer”. J. Obstet. Gynaecol., 2002, 22, 421.

[23] Andersson S., Rylander E., Larsson B., Strand A., Silfversvard C.,Wilander E.: “The role of human papillomavirus in cervical adenocarcinoma carcinogenesis”. Eur. J. Cancer, 2001, 37, 246.

[24] Castellsague X., Diaz M., de Sanjose S., Munoz M., Herrero R., Franceschi S., et al.: “Worldwide human papillomavirus etiology of cervical adenocarcinoma and its cofactors: implications for screening and prevention. J. Natl. Cancer Inst., 2006, 98, 303.

[25] Ronco G., Dillner J., Elfstrom K.M., Tunesi S., Snijders P.J.F., Arbyn M., et al.: “Efficacy of HPV-based screening for prevention of invasive cervical cancer: follow-up of four European randomised controlled trials”. Lancet, 2014, 383, 524.

[26] Open Society Foundations: “Mapping Digital Media: Jordan”. Available at: https://www.opensocietyfoundations.org/sites/default/files/mapping-digital-media-jordan-20131121.pdf

[27] Bosch F.X., Lorincz A., Muñoz .N, Meijer C.J., Shah K.V.: “The causal relation between human papillomavirus and cervical cancer”. J. Clin. Pathol., 2002, 55, 244.